Background: Aspirin is known to reduce the risk of cardiovascular events by 25% in patients with arterial vascular disease. However, the phenomena of "aspirin resistance" may result in a higher rate of adverse outcomes in such patients. We sought to determine the prevalence of aspirin resistance with the novel cartridge for the Ultegra Rapid Platelet Function Analyzer (RPFA-ASA) after one dose of non-enteric coated aspirin (325-mg) in subjects with multiple risk factors for cardiovascular disease. Methods: Data from 148 subjects were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 2-30 hours (post-aspirin). Aspirin response units (ARU) stimulated by cationic propyl gallate were measure by Ultegra RPFA-ASA, while 5µM epinephrine-induced conventional aggregometry was used as a reference. Results: A single dose of aspirin decreases ARU from 647±95 to 436±69, matching closely the diminished aggregation from 72±21% to 25±10%. Figure 1 demonstrates the ranges of responses in ARU's for patients prior and after aspirin ingestion. There is an area of overlap where both pre-ASA and post-ASA measurements fall, and it is not possible to assay with any assurance that platelet function has been effectively suppressed by the ASA, regardless of the test result prior to therapy. The use of the equivocal (yellow) zone increases the reliability of a posteriori assignment of a patient into an effectiveness group, since it refuses to supply a decision in cases where there is high variability in the decision. The range of 550 and above as a non-responder, 500 to 550 as the equivocal zone, and less than than 550 as an aspirin responder results in the optimal boundaries to minimize the errors-of-classification. Conclusion: The timely detection of aspirin resistance is critical for adequate management of antithrombotic regimens. The Ultegra RPFA-ASA is a novel, fast method that could be used in clinical practice for monitoring of aspirin efficacy, and early detection of aspirin resistance.
BACKGROUND:Selective cyclooxygenase-2 (COX-2) inhibitors are effective anti-inflammatory agents, and their use results in a lower rate of ulcers and their complications compared to non-selective NSAIDs. However, questions have been raised about a possible adverse effect on CV outcomes. METHODS: 433 patients with osteoarthritis were randomized (double-blind) to etoricoxib 90 mg qd, celecoxib 200 mg bid, ibuprofen 800 mg tid, or placebo for 12 weeks. LDL cholesterol, homocysteine, fibrinogen, and CRP were measured at baseline, and at 6 and 12 weeks. The primary hypothesis was that etoricoxib is non-inferior to placebo in its effect on all four biomarkers based on an "on-treatment" analysis. Non-inferiority margins (20% for LDL, fibrinogen and homocysteine, and 80% for CRP) were pre-defined for each biomarker based on published data. RESULTS: Etoricoxib was non-inferior to placebo on all four biomarkers after 12 weeks (Table) . Etoricoxib was also non-inferior to celecoxib and ibuprofen. The effect of etoricoxib on CRP was greater in patients who smoked (46% reduction vs placebo), with diabetes (51%) or with higher Framingham CV risk score (32%). CONCLUSION: Etoricoxib was comparable to placebo, celecoxib, and ibuprofen in its effect on four established biomarkers of CV risk. While clinical outcomes data will provide a more definitive CV safety profile for COX-2 inhibitors, these data provide reassurance that selective COX-2 inhibition does not have an adverse effect on these known markers of CV risk. Introduction: In vitro, the angiotensin II type 2 receptor (AT2-R) exerts antiproliferative effects in the cardiovascular system. Moreover, the G1675A gene polymorphism of the AT2-R has been shown to influence left ventricular structure in essential hypertensive subjects. We hypothesized that this gene polymorphism may also alter the cardiac structural response to antihypertensive therapy, in particular to agents interfering with the renin-angiotensin-system. Methods: In the Cardiovascular Irbesartan Project (CVIP), a double blind randomized clinical study, patients with mild-to-moderate essential hypertension and early target organ damage as evidenced by an increased intima media thickness (IMT) of the common carotid artery (0.8-1.5 mm) were treated with either irbesartan or atenolol for 18 months. The G1675A genotype of the AT2-R gene was determined by a 5' nuclease allelic discrimination assay using real-time PCR in 112 subjects. Results: At baseline, blood pressure and left ventricular mass index (LVMI) were similar between genotypes. In addition, after 6 and after 18 months, blood pressure control was similar between genotypes. However, G allele carriers (males with G genotype and females with GG or GA genotype, n=62) showed an increase in LVMI while hemizygous males and females with the AA genotype (n=50) showed a decrease in LVMI (+2.5±20.4 vs -8.8±25.0 g/m 2 , p=0.02 after 6 months and +6.6±26.3 vs -11.4±21.9 g/m 2, , p=0.002 after 18 months). These differences were also observed in both treatment subgroups to a similar extent. Conclusion: The A allele of the G1675A polymorphism of the AT2-R was associated with a favorable response of cardiac structure to antihypertensive therapy, regardless of the type of treatment. 
